XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2016
Summary of Significant Accounting Policies  
Schedule of assets that are required to be measured at fair value on a recurring basis

As of September 30, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis.  The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at September 30, 2016 Using

 

 

 

 

 

 

Quoted Prices in

 

 

 

 

Significant

 

 

 

 

 

 

Active Markets for

 

Significant Other

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Observable Inputs

 

Inputs

 

 

    

Total

   

(Level 1)

    

(Level 2)

    

(Level 3)

 

Cash equivalents

 

$

172,058

 

$

172,058

 

$

 —

 

$

 —

 

 

As of June 30, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. The following table represents the fair value hierarchy for the Company’s financial assets measured at fair value on a recurring basis as of June 30, 2016 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at June 30, 2016 Using

 

 

 

 

 

 

Quoted Prices in

 

 

 

 

Significant

 

 

 

 

 

 

Active Markets for

 

Significant Other

 

Unobservable

 

 

 

 

 

 

Identical Assets

 

Observable Inputs

 

Inputs

 

 

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

Cash equivalents

 

$

219,918

 

$

219,918

    

$

 —

    

$

 —

 

 

Schedule of inventory

Inventory at September 30, 2016  and June 30, 2016 is summarized below (in thousands):

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

June 30,

 

 

    

2016

    

2016

 

Raw materials

 

$

191

 

$

317

 

Work in process

 

 

1,836

 

 

590

 

Total

 

$

2,027

 

$

907

 

 

Schedule of common stock equivalents, as calculated in accordance with the treasury-stock method

 

The Company’s common stock equivalents, as calculated in accordance with the treasury‑stock method for the options and the if-converted method for the convertible notes, are shown in the following table (in thousands):

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

    

2016

    

2015

 

Options outstanding to purchase common stock and unvested restricted stock

 

14,929

    

11,494

 

Common stock equivalents under treasury stock method for options

 

3

 

1,296

 

Shares issuable upon conversion of convertible notes

 

23,878

 

 —

 

Common stock equivalents under if-converted method for convertible notes

 

23,878

 

 —

 

 

Schedule of risk-free rate of the stock options based on US Treasury rate

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

 

    

2016

    

2015

 

Dividend

 

None

    

None

 

Volatility

 

65.65

%  

67.07

%  

Risk-free interest rate

 

1.26

%  

1.89

%  

Expected life (years)

 

6.3

 

6.3

 

 

Summary of stock option activity

A summary of option activity under the 2006 Plan as of September 30, 2016, and changes during the three month period then ended is presented below (in thousands, except weighted-average data):

 

 

 

 

 

 

 

 

    

 

    

Weighted

 

 

Number of

 

Average

 

 

Stock

 

Exercise

 

 

Options

 

Price

Outstanding at June 30, 2016

 

11,813

 

$

13.03

Granted

 

3,341

 

$

2.95

Exercised

 

 —

 

$

0.00

Forfeited/Canceled

 

(436)

 

$

10.41

Outstanding at September 30, 2016

 

14,718

 

$

10.82

 

Schedule of percentage of total revenues recognized from each significant customer

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

September 30,

 

 

Collaborative Partner:

    

2016

    

2015

 

 

Biotest

 

1

%

16

%

 

Lilly

 

1

%  

35

%  

 

Roche

 

81

%  

38

%